BioSpace News Archive

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 9, 2021.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 5, 2021 to all shareholders of record as of March 15, 2021.

Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS).

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Shattuck management will participate in two upcoming investor conferences.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that China’s National Medical Products Administration

WuXi Diagnostic Investment (Cayman) Limited (“WuXi Diagnostics”) announced that it has completed US$150 million in series B funding, joined by new investors including Thermo Fisher Scientific Inc. (“Thermo Fisher”), Shiyu Capital (“SHIYU”),

Light therapy, also known as phototherapy, uses daylight or some equivalent form of light to treat a wide range of mental illnesses and skin disorders.

SIA (Surgical Innovation Associates), an early growth-stage medical technology company, announced today that the first patient has been enrolled in a pivotal trial of its flagship absorbable mesh, DuraSorb®, under an investigational device exemption (IDE) from the United States Food and Drug Administration (US FDA).

Rise in demand for healthcare products at an affordable price point could spur the OTC drug market growth.